EXACT Therapeutics AS Logo

EXACT Therapeutics AS

EXTX | OL

Overview

Corporate Details

ISIN(s):
NO0010852205 (+1 more)
LEI:
2138006ZE5JAL39AGD55
Country:
Norway
Address:
Østre Aker vei 19, 0581 Oslo
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing Acoustic Cluster Therapy (ACT®), a proprietary technology platform that uses ultrasound for targeted drug delivery and therapeutic enhancement. The company's primary focus is oncology, with a lead program in a Phase 2 clinical trial for locally advanced pancreatic cancer. The ACT® platform employs a unique biomechanical mechanism to significantly increase the uptake of co-administered drugs into tumors and across the blood-brain barrier without damaging capillary walls. A key advantage of the technology is its compatibility with standard hospital ultrasound systems and that it does not require drug reformulation, positioning it as a versatile enhancement for various therapies.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for EXACT Therapeutics AS. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-12 08:30
Regulatory News Service
EXACT Therapeutics to Present at the European Society for Medical Oncology (ESM…
English 1.8 KB
2025-08-11 11:08
Report Publication Announcement
Financial calendar
English 430 bytes
2025-07-08 08:30
Legal Proceedings Report
EXACT Therapeutics announces grant of core patent in the U.S.
English 1.9 KB
2025-06-24 08:00
Regulatory News Service
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients w…
English 3.0 KB
2025-06-13 12:09
Director's Dealing
EXACT Therapeutics AS: Primary insider notification - Attachment: Notification …
English 41.4 KB
2025-06-13 12:09
Board/Management Information
EXACT Therapeutics AS: Primary insider notification
English 1.3 KB
2025-06-13 12:05
Post-Annual General Meeting Information
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 - Attachme…
Norwegian 729.7 KB
2025-06-13 12:05
Post-Annual General Meeting Information
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025
English 1.3 KB
2025-06-04 09:20
Proxy Solicitation & Information Statement
EXACT Therapeutics AS – Information regarding voting at the Annual General Meet…
English 1.7 KB
2025-05-28 14:53
Pre-Annual General Meeting Information
EXACT Therapeutics AS - Notice of Annual General Meeting 2025 - Attachment: AGM…
Norwegian 1.1 MB
2025-05-28 14:53
Pre-Annual General Meeting Information
EXACT Therapeutics AS - Notice of Annual General Meeting 2025
English 1.4 KB
2025-05-20 06:30
Regulatory News Service
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial i…
English 115.9 KB
2025-05-20 06:30
Regulatory News Service
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial i…
English 6.5 KB
2025-05-14 06:35
Regulatory News Service
EXACT Therapeutics announces grant of key patent covering non-invasive delivery…
English 2.1 KB
2025-05-07 08:47
Regulatory News Service
EXACT Therapeutics announces grant of key patent in Japan
English 1.9 KB

Automate Your Workflow. Get a real-time feed of all EXACT Therapeutics AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for EXACT Therapeutics AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN